Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Knowing what to include helps you prepare quickly. This intro highlights essential categories and a simple framework for an effective emergency budget.
15,369 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
When a major investor exits a growing SaaS company, the move can shake confidence and the stock. This article examine...
As the cost of nursing-home care climbs past six figures annually, medicare won’t touch long-term care costs, forcing...
Life360 faced a tough week as investors digested a mixed earnings report. This article explains the drivers behind th...
AI growth drives data-center electricity demand, creating opportunities for energy players with long-term contracts. ...
Analysts warn that a move to $100 oil would erode Delta and United's 2026 earnings guidance, likely pushing shares lo...
Income-focused investors face a tricky mood: chase reliable payouts or risk capital. Learn about three high-yield div...
With bond yields getting slashed, income-minded investors are turning to dividend stocks that blend steady payouts wi...
Amazon just announced shocking debt plans to fund its data-center expansion. This in-depth analysis breaks down what ...
New to investing? Discover a practical, evidence-based approach to the allocation of assets for beginner investors. L...
London-based Valarian secures a $50 million Series A led by NEA to deploy ACRA, a sovereignty-focused layer that lets...
A Goldman Sachs note presents a bullish scenario where gold could hit $5,400 per ounce. The outlook reverberates thro...